0001104659-20-022100.txt : 20200214
0001104659-20-022100.hdr.sgml : 20200214
20200214180822
ACCESSION NUMBER: 0001104659-20-022100
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200212
FILED AS OF DATE: 20200214
DATE AS OF CHANGE: 20200214
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: COLLIER EARL M JR
CENTRAL INDEX KEY: 0001201254
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34058
FILM NUMBER: 20622389
MAIL ADDRESS:
STREET 1: C/O TESARO, INC.
STREET 2: 1000 WINTER STREET, SUITE 3300
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CAPRICOR THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001133869
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 8840 WILSHIRE BLVD
STREET 2: 2ND FLOOR
CITY: BEVERLY HILLS
STATE: CA
ZIP: 90211
BUSINESS PHONE: (310) 358-3200
MAIL ADDRESS:
STREET 1: 8840 WILSHIRE BLVD
STREET 2: 2ND FLOOR
CITY: BEVERLY HILLS
STATE: CA
ZIP: 90211
FORMER COMPANY:
FORMER CONFORMED NAME: Nile Therapeutics, Inc.
DATE OF NAME CHANGE: 20070920
FORMER COMPANY:
FORMER CONFORMED NAME: SMI PRODUCTS INC
DATE OF NAME CHANGE: 20010206
4
1
tm208086d3_4.xml
OWNERSHIP DOCUMENT
X0306
4
2020-02-12
0
0001133869
CAPRICOR THERAPEUTICS, INC.
CAPR
0001201254
COLLIER EARL M JR
C/O CAPRICOR THERAPEUTICS, INC.
8840 WILSHIRE BLVD., 2ND FLOOR
BEVERLY HILLS
CA
90211
1
0
0
0
Stock Option (Right to Buy)
1.39
2020-02-12
4
A
0
4750
A
2029-08-08
Common Stock
4750
4750
D
Stock Option (Right to Buy)
1.39
2020-02-12
4
A
0
3050
A
2028-01-02
Common Stock
3050
3050
D
Stock Option (Right to Buy)
1.39
2020-02-12
4
A
0
2856
A
2027-01-03
Common Stock
2856
2856
D
Stock Option (Right to Buy)
1.39
2020-02-12
4
A
0
2437
A
2026-06-02
Common Stock
2437
2437
D
Stock Option (Right to Buy)
1.39
2020-02-12
4
A
0
750
A
2025-03-03
Common Stock
750
750
D
Stock Option (Right to Buy)
1.39
2020-02-12
4
A
0
1401
A
2023-03-06
Common Stock
1401
1401
D
Stock Option (Right to Buy)
1.39
2020-02-12
4
A
0
15455
A
2022-04-27
Common Stock
15455
15455
D
Stock Option (Right to Buy)
3.25
2020-02-12
4
D
0
4750
D
2029-08-08
Common Stock
4750
0
D
Stock Option (Right to Buy)
15.70
2020-02-12
4
D
0
3050
D
2028-01-02
Common Stock
3050
0
D
Stock Option (Right to Buy)
25.50
2020-02-12
4
D
0
2856
D
2027-01-03
Common Stock
2856
0
D
Stock Option (Right to Buy)
31.20
2020-02-12
4
D
0
2437
D
2026-06-02
Common Stock
2437
0
D
Stock Option (Right to Buy)
57.80
2020-02-12
4
D
0
750
D
2025-03-03
Common Stock
750
0
D
Stock Option (Right to Buy)
3.70
2020-02-12
4
D
0
1401
D
2023-03-06
Common Stock
1401
0
D
Stock Option (Right to Buy)
3.70
2020-02-12
4
D
0
15455
D
2022-04-27
Common Stock
15455
0
D
3,000 of the shares were vested on the date of grant. The remaining 1,750 shares will vest 1/48th on the first day of each month, commencing September 1, 2019, until the stock option becomes fully vested and exercisable. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting.
The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share.
1,050 of the shares will vest 1/48th on the first day of each month, commencing February 1, 2018, until the stock option becomes fully vested and exercisable. The remaining 2,000 shares will vest 1/12th on the first day of each month, commencing February 1, 2018, with the last month vesting on December 31, 2018. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting.
856 of the shares will vest 1/48th on the first day of each month, commencing February 1, 2017, until the stock option becomes fully vested and exercisable. The remaining 2,000 shares will vest 1/12th on the first day of each month, commencing February 1, 2017, with the last month vesting on December 31, 2017. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting.
The stock option award is fully vested and exercisable.
/s/ Linda Marban, as Attorney-in-Fact
2020-02-14